A Phase 3 interventional study of Atogepant in Chronic Migraine, sponsored by AbbVie. Completed at 29 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing atogepant in Migraine Disorders — 6 open to participants now, 7 under way, 4 of them phase 3. atogepant · Migraine Disorders.
Among the 21 studies testing atogepant in Migraine Disorders, this one is the 19th largest by enrollment, is one of 2 that started in 2022, is one of 15 in phase 3, and was the 11th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →6 of the 21 studies testing atogepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–70
AbbVie · Sites in United States, Canada, Denmark and 8 more countries
Ages 12–17
AbbVie · Sites in United States, Belgium, Canada and 13 more countries
Ages 6–17
AbbVie · Sites in United States, Belgium, Canada and 13 more countries
Ages 6–17
Konrad Peter Weber · Sites in Switzerland
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
atogepant: first FDA approval 2021 (QULIPTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 16 · Phase 4 4
First in 2016; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 75 is close to the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 468 across the 21 interventional studies. Of the 14 that completed or were terminated, 11 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 21 have an industry lead sponsor. The 5 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
55 studies in Migraine Disorders by AbbVie: 9 open now, 13 under way, 7 of them phase 3. Of 40 finished, 32 (80%) have results posted.
Among the 55 studies in Migraine Disorders by AbbVie, this one is the 35th largest by enrollment of the 41 interventional ones that give a count, is one of 5 that started in 2022, is one of 30 in phase 3, and was the 38th registered.
AbbVie’s Migraine Disorders studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing atogepant in Migraine Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 55 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
Migraine is characterized by attacks of throbbing, moderate or severe headache, often associated with nausea, vomiting, and/or sensitivity to light and/or sound. The study will assess safety and tolerability of atogepant when added to BOTOX, as well as prospectively evaluate the efficacy of add-on atogepant for migraine prevention. Adverse events and change in disease activity will be monitored.
Atogepant is an investigational drug being developed to prevent chronic migraine. Approximately 75 adult participants will be enrolled at approximately 30 sites in the United States.
All participants will receive atogepant oral tablet once a day (QD) during the 24-week treatment period, in addition to their standard of care Botox.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received atogepant 60 mg once a day (QD) during the 24-week treatment period.
Drug: Atogepant
Oral Tablet
Also known as: QULIPTA
Number of Participants With Adverse Events (AEs)
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.
Time frame: From first dose of study drug until 4 weeks following last dose of study drug (up to 28 weeks)
Percentage of Participants With Potentially Clinically Significant (PCS) Laboratory Values (Chemistry, Hematology, Urinalysis) as Assessed by the Investigator
Clinical laboratory test values are considered PCS if they meet either the lower-limit or higher-limit PCS criteria defined in the categories below. The percentage of participants with PCS laboratory values are summarized for hematology, chemistry, and urinalysis. Glomerular Filtration Rate (GFR) is a clinical measurement that calculates how many milliliters of blood the kidneys filter every second. Glucose, Urinalysis: At least 1+ indicates that the urine contains an increased concentration of sugar. Protein, Urinalysis: At least 1+ indicates that the urine contains an increased concentration of protein.
Time frame: From first dose of study drug until last dose of study drug (24 weeks)
Percentage of Participants With Potentially Clinically Significant (PCS) Vital Sign Measurements as Assessed by the Investigator
Potentially Clinically Significant post-Baseline vital sign values are summarized for categories: systolic and diastolic blood pressures \[sitting\], pulse rate \[sitting\], and weight. Number of participants with non-PCS baseline values who met the PCS criterion at least once post-baseline are reported.
Time frame: From first dose of study drug until last dose of study drug (24 weeks)
Percentage of Participants With Most Severe Suicidal Ideation and Suicidal Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) During the Open-Label Treatment Period
The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. (Minimum total score 0, maximum total score 5; higher total scores indicate more suicidal ideation and/or suicidal behavior).
Time frame: From first dose of study drug until last dose of study drug (24 weeks)
Percentage of Participants With Potentially Clinically Significant (PCS) Electrocardiograms (ECGs) Findings as Assessed by the Investigator
12-lead ECGs were performed at select study visits.
Time frame: From first dose of study drug until last dose of study drug (24 weeks)
The screening/baseline period was up to 12 weeks, which included at least 28 days of eDiary collection of migraine days and headache days at the end of the screening/baseline period.
| Milestone | All Participants |
|---|---|
| Started | 75 |
| Completed | 57 |
| Not completed | 18 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Withdrawal by subject | 11 |
| Withdrew: Other | 4 |
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.
| Participants | All Participants |
|---|---|
| Any Treatment-emergent Adverse Event (TEAE) | 49 |
| AE with reasonable possibility of being related to atogepant | 22 |
| AE with reasonable possibility of being related to BOTOX | 1 |
| Any severe TEAE | 2 |
| Any Treatment-emergent Serious Adverse Event (TESAE) | 2 |
| AE leading to withdrawal of atogepant study treatment | 7 |
| AE leading to withdrawal of BOTOX treatment | 2 |
| Any TEAE leading to death | 0 |
Clinical laboratory test values are considered PCS if they meet either the lower-limit or higher-limit PCS criteria defined in the categories below. The percentage of participants with PCS laboratory values are summarized for hematology, chemistry, and urinalysis. Glomerular Filtration Rate (GFR) is a clinical measurement that calculates how many milliliters of blood the kidneys filter every second. Glucose, Urinalysis: At least 1+ indicates that the urine contains an increased concentration of sugar. Protein, Urinalysis: At least 1+ indicates that the urine contains an increased concentration of protein.
| number of participants | All Participants |
|---|---|
| Basophils (10^9/L): > 2.0 x Upper Limit of Normal (ULN) | 0 |
| Eosinophils (10^9/L): > 2.0 x Upper Limit of Normal (ULN) | 0 |
| Erythrocytes, Hematology (10^12/L): < 0.9 x Lower Limit of Normal (LLN) | 1 |
| Erythrocytes, Hematology (10^12/L): > 1.1 x Upper Limit of Normal (ULN) | 0 |
| Hematocrit (RATIO): < 0.9 x Lower Limit of Normal (LLN) | 0 |
| Hematocrit (RATIO): > 1.1 x Upper Limit of Normal (ULN) | 0 |
| Hemoglobin (g/L): < 0.9 x Lower Limit of Normal (LLN) | 0 |
| Hemoglobin (g/L): > 1.1 x Upper Limit of Normal (ULN) | 0 |
| Leukocytes, Hematology (10^9/L): < 0.9 x Lower Limit of Normal (LLN) | 1 |
| Leukocytes, Hematology (10^9/L): > 1.5 x Upper Limit of Normal (ULN) | 0 |
| Lymphocytes (10^9/L): < 0.7 x Lower Limit of Normal (LLN) | 2 |
| Lymphocytes (10^9/L): > 1.3 x Upper Limit of Normal (ULN) | 0 |
| Monocytes (10^9/L): < 0.5 x Lower Limit of Normal (LLN) | 0 |
| Monocytes (10^9/L): > 2.0 x Upper Limit of Normal (ULN) | 0 |
| Neutrophils (10^9/L): < 0.7 x Lower Limit of Normal (LLN) | 1 |
| Neutrophils (10^9/L): > 1.3 x Upper Limit of Normal (ULN) | 2 |
| Platelets (10^9/L): < 0.5 x Lower Limit of Normal (LLN) | 0 |
| Platelets (10^9/L): > 1.5 x Upper Limit of Normal (ULN) | 0 |
| Alanine Aminotransferase (U/L): ≥ 3.0 x Upper Limit of Normal (ULN) | 0 |
| Albumin (g/L): < 0.8 x Lower Limit of Normal (LLN) | 0 |
| Albumin (g/L): > 1.2 x Upper Limit of Normal (ULN) | 0 |
| Alkaline Phosphatase (U/L): ≥ 3.0 x Upper Limit of Normal (ULN) | 0 |
| Aspartate Aminotransferase (U/L): ≥ 3.0 x Upper Limit of Normal (ULN) | 0 |
| Bicarbonate (mmol/L): < 0.9 x Lower Limit of Normal (LLN) | 3 |
| Bicarbonate (mmol/L): > 1.1 x Upper Limit of Normal (ULN) | 0 |
| Bilirubin, Chemistry (umol/L): ≥ 1.5 x Upper Limit of Normal (ULN) | 0 |
| Calcium (mmol/L): < 0.9 x Lower Limit of Normal (LLN) | 0 |
| Calcium (mmol/L): > 1.1 x Upper Limit of Normal (ULN) | 0 |
| Chloride (mmol/L): < 0.9 x Lower Limit of Normal (LLN) | 0 |
| Chloride (mmol/L): > 1.1 x Upper Limit of Normal (ULN) | 0 |
| Cholesterol (mmol/L): > 1.6 x Upper Limit of Normal (ULN) | 0 |
| Creatine Kinase (U/L): > 2.0 x Upper Limit of Normal (ULN) | 4 |
| Creatinine (umol/L): > 1.5 x Upper Limit of Normal (ULN) | 0 |
| Glomerular Filtration Rate, Estimated (mL/sec/1.73m^2): < 1 mL/sec/1.73m^2 | 4 |
| Glucose, Chemistry (mmol/L): < 0.8 x Lower Limit of Normal (LLN) | 3 |
| Glucose, Chemistry (mmol/L): > 2.0 x Upper Limit of Normal (ULN) | 1 |
| Lactate Dehydrogenase (U/L): > 3.0 x Upper Limit of Normal (ULN) | 0 |
| Phosphate (mmol/L): < 0.9 x Lower Limit of Normal (LLN) | 1 |
| Phosphate (mmol/L): > 1.1 x Upper Limit of Normal (ULN) | 0 |
| Potassium (mmol/L): < 0.9 x Lower Limit of Normal (LLN) | 0 |
| Potassium (mmol/L): > 1.1 x Upper Limit of Normal (ULN) | 1 |
| Protein, Chemistry (g/L): < 0.9 x Lower Limit of Normal (LLN) | 1 |
| Protein, Chemistry (g/L): > 1.1 x Upper Limit of Normal (ULN) | 0 |
| Sodium (mmol/L): < 0.9 x Lower Limit of Normal (LLN) | 0 |
| Sodium (mmol/L): > 1.1 x Upper Limit of Normal (ULN) | 0 |
| Urate (umol/L): > 1.2 x Upper Limit of Normal (ULN) | 0 |
| Urea Nitrogen (mmol/L): > 1.5 x Upper Limit of Normal (ULN) | 0 |
| Glucose, Urinalysis: At least 1+ | 2 |
| Protein, Urinalysis: At least 1+ | 16 |
| Specific Gravity: > 1.1 x Upper Limit of Normal (ULN) | 0 |
| pH: < 0.9 x Lower Limit of Normal (LLN) | 0 |
| pH: > 1.1 x Upper Limit of Normal (ULN) | 0 |
Potentially Clinically Significant post-Baseline vital sign values are summarized for categories: systolic and diastolic blood pressures \[sitting\], pulse rate \[sitting\], and weight. Number of participants with non-PCS baseline values who met the PCS criterion at least once post-baseline are reported.
| number of participants | All Participants |
|---|---|
| Sitting Systolic Blood Pressure (mmHg): ≥ 180 and increase from Baseline of ≥ 20 | 0 |
| Sitting Systolic Blood Pressure (mmHg): ≤ 90 and decrease from Baseline of ≥ 20 | 0 |
| Sitting Diastolic Blood Pressure (mmHg): ≥ 105 and increase from Baseline of ≥ 15 | 1 |
| Sitting Diastolic Blood Pressure (mmHg): ≤ 50 and decrease from Baseline of ≥ 15 | 1 |
| Sitting Pulse Rate (bpm): ≥ 120 and increase from Baseline of ≥ 15 | 0 |
| Sitting Pulse Rate (bpm): ≤ 50 and decrease from baseline of ≥ 15 | 0 |
| Weight (kg): Increase from Baseline of ≥ 7% | 6 |
| Weight (kg): Decrease from Baseline of ≥ 7% | 6 |
The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. (Minimum total score 0, maximum total score 5; higher total scores indicate more suicidal ideation and/or suicidal behavior).
| number of participants | All Participants |
|---|---|
| No suicidal ideation | 73 |
| Suicidal ideation | 0 |
| Most severe suicidal ideation: Active suicidal ideation with specific plan and intent | 0 |
| Most severe suicidal ideation: Active suicidal ideation with some intent to act, w/out specific plan | 0 |
| Most severe suicidal ideation: Active suicidal ideation w/ any method (not plan) w/out intent to act | 0 |
| Most severe suicidal ideation: Non-specific active suicidal thoughts | 0 |
| Most severe suicidal ideation: Wish to be dead | 0 |
| No suicidal behavior | 73 |
| Suicidal behavior | 0 |
| Most severe suicidal behavior: Actual attempt | 0 |
| Most severe suicidal behavior: Interrupted attempt | 0 |
| Most severe suicidal behavior: Aborted attempt | 0 |
| Most severe suicidal behavior: Preparatory acts or behavior | 0 |
| Completed Suicide | 0 |
| Non-suicidal self-injurious behavior | 1 |
12-lead ECGs were performed at select study visits.
| number of participants | All Participants |
|---|---|
| PR Interval (msec): ≥ 250 | 0 |
| QRS Interval (msec): ≥ 150 | 0 |
| QTcF Interval (msec): > 500 | 0 |
| QTcF Interval (msec): Increase from Baseline of > 60 | 0 |
Collected over All-cause mortality and adverse event tables include events reported from enrollment to the end of the study. The median time on follow-up was 225 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Participants | 0/75 (0%) | 2/75 (2.7%) | 29/75 (38.7%) |
| Event | All Participants |
|---|---|
| HAEMATEMESISGastrointestinal disorders | 1/75 |
| INTERVERTEBRAL DISC PROTRUSIONMusculoskeletal and connective tissue disorders | 1/75 |
| Event | All Participants |
|---|---|
| CONSTIPATIONGastrointestinal disorders | 12/75 |
| NAUSEAGastrointestinal disorders | 10/75 |
| URINARY TRACT INFECTIONInfections and infestations | 6/75 |
| DECREASED APPETITEMetabolism and nutrition disorders | 5/75 |
| COVID-19Infections and infestations | 4/75 |
Safety Population
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 47.7 ± 13.68 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 67 |
| Male | 8 |
| Ethnicity (NIH/OMB)(Participants) | All Participants |
|---|---|
| Hispanic or Latino | 6 |
| Not Hispanic or Latino | 69 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | All Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 73 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Mar 2022 to primary completion in May 2025, 37 months.
Results were first posted in Jun 2026, 1 year 1 month after primary completion.
Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 37 months is above that.
Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atogepant